Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: SERF2

Gene summary for SERF2

Gene summary.

Gene information	Species	Human
	Gene symbol	SERF2
	Gene ID	10169
	Gene name	small EDRK-rich factor 2
	Gene Alias	4F5REL
	Cytomap	15q15.3
	Gene Type	protein-coding
	GO ID	GO:0008150
	UniProtAcc	P84101

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
10169	SERF2	SYSMH3	Human	Oral cavity	OSCC	9.07e-45	3.45e+00	0.2442
10169	SERF2	SYSMH4	Human	Oral cavity	OSCC	9.40e-41	1.28e+00	0.1226
10169	SERF2	SYSMH5	Human	Oral cavity	OSCC	2.37e-32	2.06e+00	0.0647
10169	SERF2	SYSMH6	Human	Oral cavity	OSCC	7.39e-32	2.45e+00	0.1275
10169	SERF2	HTA12-26-1	Human	Pancreas	PDAC	9.22e-04	-6.82e-01	0.3728
10169	SERF2	HTA12-29-1	Human	Pancreas	PDAC	6.42e-15	-6.46e-01	0.3722
10169	SERF2	3829-EC	Human	Pancreas	PanIN	1.30e-16	5.43e-02	0.009
10169	SERF2	4347-EC	Human	Pancreas	PanIN	3.37e-16	-1.94e-01	0.0572
10169	SERF2	181429	Human	Pancreas	PDAC	1.44e-03	4.24e-01	0.1416
10169	SERF2	DS20191261Tumor	Human	Pancreas	PDAC	1.65e-09	-2.07e-01	0.1367
10169	SERF2	GSM5252126_BPH283PrGF_Via	Human	Prostate	BPH	1.27e-27	1.02e+00	-0.1771
10169	SERF2	GSM5252127_BPH283PrSF_Via	Human	Prostate	BPH	1.14e-17	6.04e-01	-0.1453
10169	SERF2	GSM5252128_BPH327PrGF_Via	Human	Prostate	BPH	8.62e-22	7.77e-01	-0.1688
10169	SERF2	GSM5252129_BPH327PrSF_Via	Human	Prostate	BPH	1.03e-29	9.81e-01	-0.1697
10169	SERF2	GSM5252130_BPH340PrGF_Via	Human	Prostate	BPH	4.65e-44	1.85e+00	-0.1972
10169	SERF2	GSM5252131_BPH340PrSF_Via	Human	Prostate	BPH	1.11e-52	1.35e+00	-0.2126
10169	SERF2	GSM5252132_BPH389PrGF	Human	Prostate	BPH	6.12e-13	1.32e+00	-0.2247
10169	SERF2	GSM5252133_BPH389PrSF	Human	Prostate	BPH	1.02e-11	1.41e+00	-0.2027
10169	SERF2	GSM5252134_BPH511PrG_Fcol_3GEX	Human	Prostate	BPH	1.69e-13	8.84e-01	-0.1433
10169	SERF2	GSM5252135_BPH511PrPUr_Fcol_3GEX	Human	Prostate	BPH	9.20e-32	1.68e+00	-0.1833

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00316479	Breast	Precancer	regulation of protein stability	38/1080	298/18723	3.73e-06	1.19e-04	38
GO:003164714	Breast	IDC	regulation of protein stability	50/1434	298/18723	1.14e-07	6.57e-06	50
GO:003164724	Breast	DCIS	regulation of protein stability	51/1390	298/18723	1.63e-08	1.15e-06	51
GO:003164710	Cervix	CC	regulation of protein stability	63/2311	298/18723	1.14e-05	2.45e-04	63
GO:0031647	Colorectum	AD	regulation of protein stability	108/3918	298/18723	6.33e-10	5.08e-08	108
GO:00316471	Colorectum	SER	regulation of protein stability	86/2897	298/18723	2.56e-09	2.42e-07	86
GO:00316472	Colorectum	MSS	regulation of protein stability	103/3467	298/18723	2.52e-11	3.49e-09	103
GO:00316473	Colorectum	MSI-H	regulation of protein stability	43/1319	298/18723	5.66e-06	2.86e-04	43
GO:00316474	Colorectum	FAP	regulation of protein stability	70/2622	298/18723	6.60e-06	2.04e-04	70
GO:00316475	Colorectum	CRC	regulation of protein stability	58/2078	298/18723	1.38e-05	4.37e-04	58
GO:003164716	Endometrium	AEH	regulation of protein stability	77/2100	298/18723	1.13e-12	2.26e-10	77
GO:00316484	Endometrium	AEH	protein destabilization	12/2100	46/18723	3.91e-03	2.64e-02	12
GO:003164717	Endometrium	EEC	regulation of protein stability	80/2168	298/18723	2.48e-13	5.96e-11	80
GO:003164812	Endometrium	EEC	protein destabilization	13/2168	46/18723	1.65e-03	1.29e-02	13
GO:003164727	Esophagus	HGIN	regulation of protein stability	96/2587	298/18723	2.21e-16	5.76e-14	96
GO:0031647111	Esophagus	ESCC	regulation of protein stability	223/8552	298/18723	5.76e-25	1.52e-22	223
GO:00316486	Esophagus	ESCC	protein destabilization	33/8552	46/18723	3.06e-04	1.83e-03	33
GO:00316477	Liver	NAFLD	regulation of protein stability	61/1882	298/18723	5.00e-08	4.71e-06	61
GO:0031648	Liver	NAFLD	protein destabilization	11/1882	46/18723	4.98e-03	3.91e-02	11
GO:003164712	Liver	Cirrhotic	regulation of protein stability	144/4634	298/18723	6.74e-19	1.28e-16	144

Page: 1 2 3

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SERF2

SNV

Missense_Mutation

c.241C>G

p.Leu81Val

p.L81V

P84101

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.672)

TCGA-AN-A0AJ-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SERF2

SNV

Missense_Mutation

c.475N>G

p.Gln159Glu

p.Q159E

P84101

protein_coding

deleterious_low_confidence(0)

benign(0.125)

TCGA-JW-A5VL-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

SERF2

SNV

Missense_Mutation

c.136A>C

p.Asn46His

p.N46H

P84101

protein_coding

tolerated_low_confidence(1)

benign(0)

TCGA-AA-3977-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

SERF2

SNV

Missense_Mutation

c.352N>G

p.Cys118Gly

p.C118G

P84101

protein_coding

deleterious_low_confidence(0.02)

benign(0.014)

TCGA-AA-A02R-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

SERF2

SNV

Missense_Mutation

c.473C>A

p.Pro158His

p.P158H

P84101

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.996)

TCGA-CK-6746-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

SERF2

SNV

Missense_Mutation

novel

c.260N>T

p.Arg87Ile

p.R87I

P84101

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.852)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

SERF2

SNV

Missense_Mutation

novel

c.418N>A

p.Asp140Asn

p.D140N

P84101

protein_coding

deleterious_low_confidence(0)

probably_damaging(0.978)

TCGA-A5-A1OF-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

SERF2

SNV

Missense_Mutation

novel

c.165N>G

p.His55Gln

p.H55Q

P84101

protein_coding

deleterious_low_confidence(0)

benign(0.036)

TCGA-S2-AA1A-01

Lung

lung adenocarcinoma

Female

>=65

I/II

Unknown

SERF2

SNV

Missense_Mutation

c.101N>T

p.Ala34Val

p.A34V

P84101

protein_coding

deleterious_low_confidence(0.02)

probably_damaging(0.992)

TCGA-34-A5IX-01

Lung

lung squamous cell carcinoma

Male

>=65

I/II

Unknown

SERF2

SNV

Missense_Mutation

novel

c.388N>T

p.Pro130Ser

p.P130S

P84101

protein_coding

tolerated_low_confidence(0.54)

benign(0.001)

TCGA-90-A4ED-01

Lung

lung squamous cell carcinoma

Male

>=65

I/II

Unknown

Page: 1 2

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1